Fennec Pharmaceuticals Presents Two-Year Pedmark Data in Japan
RESEARCH TRIANGLE PARK, N.C. — September 17, 2026 Fennec Pharmaceuticals announced the oral presentation of detailed results from the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RESEARCH TRIANGLE PARK, N.C. — September 17, 2026 Fennec Pharmaceuticals announced the oral presentation of detailed results from the...
AMSTERDAM, The Netherlands – May 6, 2026 Norgine has announced that the Australian Therapeutic Goods Administration (TGA) has granted...
